IO Biotech
IO Biotech
IOBT
NASDAQ
0.91
USD
0.00%
About
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME.
The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 234.3K |
| Three Month Average Volume | 3.3M |
| High Low | |
| Fifty-Two Week High | 2.098 USD |
| Fifty-Two Week Low | 0.8163 USD |
| Fifty-Two Week High Date | 05 Jan 2024 |
| Fifty-Two Week Low Date | 30 Oct 2023 |
| Price and Volume | |
| Current Price | 1.5 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 16.38% |
| Thirteen Week Relative Price Change | 18.77% |
| Twenty-Six Week Relative Price Change | -22.49% |
| Fifty-Two Week Relative Price Change | -34.94% |
| Year-to-Date Relative Price Change | -32.62% |
| Price Change | |
| One Day Price Change | -2.60% |
| Thirteen Week Price Change | 27.12% |
| Twenty-Six Week Price Change | -14.77% |
| Five Day Price Change | -8.54% |
| Fifty-Two Week Price Change | -18.48% |
| Year-to-Date Price Change | -20.21% |
| Month-to-Date Price Change | 11.11% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.02125 USD |
| Book Value Per Share (Most Recent Quarter) | 1.4613 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.02125 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.4613 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.50219 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.9771 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.4374 USD |
| Normalized (Last Fiscal Year) | -1.9771 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.9771 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.4374 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.9771 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.4374 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.17351 USD |
| Cash Per Share (Most Recent Quarter) | 1.52923 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.97216 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.41523 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.30386 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 57.28% |
| EPS Change (Trailing Twelve Months) | 44.01% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -100,747,000 |
| Net Debt (Last Fiscal Year) | -143,193,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -72,060,000 |
| Free Cash Flow (Trailing Twelve Months) | -80,858,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -56.91% |
| Return on Assets (Trailing Twelve Months) | -76.85% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -63.29% |
| Return on Equity (Trailing Twelve Months) | -87.66% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -62.35% |
| Return on Investment (Trailing Twelve Months) | -86.10% |
| Return on Investment (5 Year) | -99,999.99% |